Kornimate/medical-research-clean huggingface dataset:
postoperative gastroesophageal reflux symptoms after laparoscopic sleeve gastrectomy based on the presence of preoperative symptoms

Conditions: Obesity and Obesity-related Medical Conditions; Laparoscopic Sleeve Gastrectomy; Gastro-oesophageal Reflux

Summary: this study aims to investigate the patterns of reflux symptoms after laparoscopic sleeve gastrectomy based on the presence or absence of preoperative gastroesophageal reflux symptoms.

obesity is a well-known risk factor for gastroesophageal reflux disease (gerd), and laparoscopic sleeve gastrectomy (lsg) is the most commonly performed bariatric/metabolic surgery. however, patients often experience reflux symptoms after lsg, and those with severe reflux symptoms or severe erosive esophagitis have been excluded from candidates for lsg. this study aims to analyze the patterns of postoperative reflux symptoms based on the presence of preoperative reflux symptoms. prospectively established databases of patients assessed for reflux symptoms at a single institution will be retrospectively reviewed. a total of 64 patients who underwent lsg between april 2020 and march 2023 will be included in this study. the modified gerd-hrql (gerd- health-related quality of life) questionnaire was used to evaluate gastroesophageal reflux symptoms before lsg and at 1, 3, 6, 9, and 12 months after surgery. reflux symptoms will be categorized into heartburn and regurgitation, and the patterns of heartburn and regurgitation scores included in the modified gerd-hrql questionnaire will be analyzed. the patients will be classified based on the presence or absence of preoperative reflux symptoms, and the patterns of symptom scores within each group will be analyzed. we will also measure the correlation between whether hiatal hernia repair was performed with laparoscopic sleeve gastrectomy and adiposity-related parameters, including preoperative and postoperative body mass index (bmi), preoperative and postoperative waist circumference (wc), the percentage of total weight loss (%twl), and the percentage of wc reduction, and changes in postoperative symptom scores.

Eligibility criteria:
inclusion criteria: 1. patients with age greater than 19 years 2. patients who underwent laparoscopic sleeve gastrectomy from march 2019 to march 2023 3. patients with postoperative follow-up longer than one month after lsg 4. patients who answered preoperative and postoperative gerd questionnaire (korean translated version of modified gerd-hrql) exclusion criteria: 1) patients with missing or incomplete postoperative gerd questionnaires

Keywords: obesity diabetes mellitus sleeve gastrectomy gastro-esophageal reflux
the e-health application to modify oral energy intake and measure outcomes remotely in als clinical trial (eat more2)

Conditions: Amyotrophic Lateral Sclerosis

Summary: this is phase iia feasibility and tolerability study of a mobile health (mhealth) application designed to study the effects of remote dietary counseling on disease progression and quality of life. the study will consist of two phases: part i will consist of building and beta-testing the als nutrition app and part ii will consist of enrolling a larger cohort of users into the app.

the investigators' prior work has shown that nutrition is an important modifiable prognostic factor for als disease progression and survival. in the recently completed e-health application to measure outcomes remotely (eat more) clinical trial (sponsored by the als association), the investigators found that nutritional counseling supported by a mobile health (mhealth) app was associated with 0.5 points/month slower alsfrs-r progression (p=0.17) and improved quality of life (p=0.09). the investigators are now designing an als-specific app that can be used by everyone with als, including those who do not live near als centers. the app would help to address gaps in the delivery of als care by providing nutritional counseling, helping patients to manage and track their disease symptoms, and communicating with their providers. after the initial design has been tested by a group of neals patients and their caregivers, the study will advertise the app widely to recruit a larger group of als patients to measure nutrition and outcomes.

Eligibility criteria:
inclusion criteria: 1. participants with a diagnosis of als (self-reported) 2. male or female subjects aged 18 years or older. 3. participants must be capable of providing informed consent and complying with trial procedures. 4. participants must have access to an ios or android device to allow the to download the apps. exclusion criteria: 1. use of a feeding tube (g-tube or j-tube) 2. bmi\>30 kg/m2 regardless of weight loss history 3. a history of cardiovascular disease (stroke, myocardial infarction, peripheral vascular disease) 4. a history of diabetes (self-reported)
miroderm h2h dfu study

Conditions: Diabetic Foot Ulcer

Summary: this study will assess the ability of miroderm to heal difficult diabetic foot ulcers within 12 weeks of treatment.

the primary objective of this study is to determine the number of successful complete wound closures within 12 weeks of treatment with miroderm fenestrated biological wound matrix. some secondary objectives of this study include documenting the time course of wound healing and assessing changes in quality of life. the primary cohort is individuals suffering from a diabetic foot ulcer that has not been healed in the last 3 months and after at least 2 attempts with an advanced biologic. ulcer will be between 1 and 12 cm squared, less than 5 mm deep, full thickness, below the ankle, and with no exposed bone or tendon. subjects will be 18 or older, have type i or ii diabetes with adequate vascular profusion. subjects will be unable to participate if they have osteomyelitis, charcot foot, a known collagen vascular disease, are on dialyses, are immunocompromised or have an hba1c level equal to or great than 12%. this is a single-arm study with no independent variables. descriptive data to be collected will include demographics, pathology and medical history. outcome assessments: * proportion of subjects with 100% epithelialization of wound * sf-36 * adverse events

Eligibility criteria:
inclusion criteria: * 18 years old or older at time of initial visit * have type i or type ii diabetes * have a neuropathic diabetic foot ulcer with the following characteristics: * is greater than 1 cm2 and less than or equal to 12 cm2 * has failed to close following at least 2 treatments with a biologic * has been present for 90 days or longer * does not show signs of infection * is full thickness (wagner grade i or ii) * located distal to the malleolus * depth of less than or equal to 5 mm * no exposed capsule, tendon or bone * no tunneling, undermining or sinus tracts * not between the toes * be willing and able to maintain required off-loading of affected limb * be willing and able to perform necessary dressing changes * have at least one of the following: * an ankle-brachial index (abi) ≥ 0.8 * tcpo2 of ≥ 30 mmhg * a toe pressure of ≥ 50 mmhg exclusion criteria: * be pregnant or be planning to become pregnant during the study * have had a chopart's amputation (or higher) * have a history of bone cancer of the affected limb * be undergoing dialysis * have active osteomyelitis or be receiving treatment for osteomyelitis * be diagnosed with unstable charcot foot on the affected side * have an hba1c level of ≥ 12% within the past 90 days * have another ulcer within 2 cm of the study ulcer * be immunocompromised or at risk of immunosuppression as determined by the treating investigator * have a known collagen vascular disease or connective tissue disease * have received treatment of the study ulcer with a skin substitute product or topical growth factor within the past 4 weeks * be participating in another medical research study * have a sensitivity to porcine material
patients with chronic obstructive pulmonary disease at altitude

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the purpose of this study is to investigate the effect of a stay at moderate altitude on exercise performance of patients with chronic obstructive lung disease.

patients with moderate to severe copd living below 800 m, will be recruited to participate in a randomized cross-over field trial evaluating the hypothesis that exercise capacity during a 4 day sojourn at moderate altitude is reduced in comparison to low altitude. outcomes will be assessed during 2 days in zurich (490 m, low altitude baseline), 2 days at davos clavadel (1650 m), and 2 days at davos jakobshorn (2590 m). the main outcome is the 6 minute walk distance.

Eligibility criteria:
inclusion criteria: * chronic obstructive pulmonary disease (copd), gold grade 2-3 * residents at low altitude (\<800 m) exclusion criteria: * unstable condition, copd exacerbation * mild (gold 1) or very severe copd (gold 4) * requirement for oxygen therapy at low altitude residence * hypoventilation * pulmonary hypertension * more than mild or unstable cardiovascular disease * use of drugs that affect respiratory center drive * internal, neurologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (\>20 cigarettes per day), inability to perform 6 min walk test. * previous intolerance to moderate altitude (\<2600m). * exposure to altitudes \>1500m for \>2 days within the last 4 weeks before the study. * pregnant or nursing patients

Keywords: airway disease bronchitis emphysema lung
vertebral augmentation and radiotherapy of collapse spinal metastatic cancer

Conditions: Metastatic Cancers; Multiple Myeloma; Vertebral Fracture

Summary: vertebral augmentation with radiotherapy to increase the functional status and quality of life for patients with vertebral body metastatic cancers.

the study quantifies the reduction of pain and changes in quality of life associated with vertebral augmentation. this study is conducted in patients with metastatic cancer or multiple myeloma involving the spine. this study addresses the value of vertebral augmentation in combination with radiotherapy in the setting of cancer to the spine. the patient's pain, overall quality of life, and fracture development/avoidance will be compared to patients treated only with radiotherapy in the past.

Eligibility criteria:
inclusion criteria: * diagnosis of metastatic disease to the vertebra or multiple myeloma * negative pregnancy test within 2 weeks prior to registration * life expectancy of \>= 3 months and karnofsky performance status (kps) score \>= 40 * pain scale score \>=5 * pain at involved vertebral body not adequately controlled * osteolysis of vertebral bodies * must agree to practice adequate means of birth control * must sign informed consent prior to study entry * must be able to understand the english language * absence of any serious cognitive or psychiatric problems potentially hampering compliance with the study and follow-up schedule. exclusion criteria: * spinal cord compression

Keywords: vertebral bodies vertebral fracture vertebral augmentation radiotherapy vertebroplasty kyphoplasty
identification of genetic variants associated with unexpected infant death syndrome

Conditions: Sudden Infant Death; Sudden Unexplained Infant Death

Summary: this is a multicenter genetic study aimed at identifying new genes/variants associated with sudden infant death syndrome (sids) based on whole-genome sequencing of family trios

the present project is part of a more global project called biominrisk for which 3 axes will be explored: genetics (a project which will be detailed here), neurobiology and radio-anatomical. this is a multicenter (15 centers), national, non-randomized, open-label, genetic study. sudden unexpected death in infant (sudi) cases will be included (i) partly retrospectively (infants already included in the national french sudi registry) and (ii) for the other cases, prospectively at the time of care of the deceased infant by the referral center of sudi participating in the project. the parents making up the trios will be included prospectively. once the sudden infant death syndrome (sids) cases have been identified among all the included sudi cases (following the results of post-mortem examinations), whole genome sequencing (wgs) will be carried out on these sids cases and their two parents, in order to identify pathogenic allelic variants. the data generated by this sequencing will then be analyzed using a trio approach to search for de novo variants, i.e. variants present in the infant who died of sids and absent from the genome of both parents.

Eligibility criteria:
child inclusion criteria * death of a child between 0 and 2 years of age due to sudden unexpected death in infant * child included in the french sudi registry with effective participation in the biocollection * children who also meet the inclusion criteria for the biominrisk-neurobio (axis 2) and biominrisk-radio-anat (axis 3) studies in the overall biominrisk project. parents inclusion criteria * biological parents of the child included in the biominrisk study * parents who have both signed the consent form for blood collection and inclusion of their samples in the biocollection * parents beneficiaries of a social security or similar scheme child exclusion criteria: * presence of a known metabolic, genetic or syndromic pathology at the time of death parents exclusion crtiteria: * parent under guardianship * presence of a known metabolic, genetic or syndromic pathology
lung function, lci, bronchial inflammation and epigenetics of patients with bo

Conditions: Bronchiolitis Obliterans

Summary: bronchiolitis obliterans is a chronic disease in which a persistent inflammatory process leads to obliteration of the small airways. pulmonary function tests (body plethysmography with dlco, lung clearance index) are performed and the fraction of exhaled nitric oxide is measured. a blood test is following to determine the inflammatory status und collect mirna. induced sputum will be obtained.

the purpose of this study is to compare mirna pattern, lung function values, bronchial inflammation and the lung clearance index of patients with bronchiolitis obliterans aged between 6 up to 30 years of age with a matched control group. the sputum samples will be processed and quantitatively analyzed to get a profile of the cytological composition. sputum and serum samples are analyzed by quantitative real-time polymerase chain reaction (qrt-pcr) and by cytometric bead assay (cba). mirna samples will be collected, processand compared with the mirna database at http://www.mirbase.org/ methods and work programme: * measurement of nitric oxide in expired air (feno) * lung function testing with spirometry and body plethysmography * lung clearance index (lci) * bronchodilation * blood test: blood count, crp, rast, serum inflammatory mediators, (genetic markers of the non-specific pulmonary defense system), mirna analysis * induced sputum for inflammatory mediators and microbiological investigations

Eligibility criteria:
inclusion criteria: * informed consent * age between 6 an 35 years * known bronchiolitis obliterans (group bronchiolitis)/ no bronchiolitis obliterans (group matched controls) * ability to perform lung function tests and inhale correctly exclusion criteria: * \<6 years of age * \>35 years of age * acute systemic or bronchial inflammation * other chronic diseases or infection (e.g. hiv, tbc, malignoma) * pregnancy * alcohol, drug or illegal drug abuse * disability to register the range and consequences of the study * actual participation in another study

Keywords: induced sputum lung clearance index mirna inflammation chronic lung disease
the impact of pain assessment on the hospital length of stay of patients in a rehabilitation unit

Conditions: Pain

Summary: the financing of the belgian hospitals is based on a system taking into account the length of hospitalization of a given patient according to his/her pathology, his/her age and his/her geriatric characteristics. this system encourages all hospital to lower the hospitalization duration to the national average for these criteria. this results in better efficiency in the management of hospitalizations but also means a swifter transfer to structures exempted from this system such as revalidation units, nursing homes and psychiatric units. an assessment of the differences in the medical practice, in terms of quality and outcomes of care, is essential for any reform willing to reduce medical costs. pain management is part of the quality indicators within hospitals. pain is defined by the international association for the study of pain as "an unpleasant sensory and emotional experience, associated to present or potential tissue damage, or described in terms of such a damage". several studies have showed that pain affects the quality of life and impacts the daily activities. acute or chronic pain can cause adverse symptoms such as sleep disturbance, appetite loss, decreased concentration, mood changes and the disruption of familial, work and social activities. pain might also slow down revalidation processes. a study performed by aprile et al showed that pain negatively influenced the rehabilitation program of a quarter of the patients having had a stroke. the functional recovery was slower and the costs were higher. the aim of this study is to determine if the systematic evaluation of the pain of a patient hospitalized in a revalidation unit has an impact on his/her length of stay.


Eligibility criteria:
inclusion criteria: * sequential inclusion of all patients hospitalized in the chronic revalidation hospital unit of the chu brugmann - queen astrid site exclusion criteria: * pathological cognitive state (mms\<23/30)

Keywords: pain hospital length of stay revalidation unit
assessment of periprosthetic bone mineral density in patients undergoing total knee prosthesis of different design

Conditions: Periprosthetic Osteolysis

Summary: compare changes in bmd via dxa at the level of the femoral and tibial periprosthetic bone between two groups of patients undergoing cemented tka of different design (posterior stabilization vs posterior cruciate preservation) with proms at a 2-year follow-up.


Eligibility criteria:
inclusion criteria: 1. patients aged ≥ 45 years 2. patients who are candidates for primary cemented total knee replacement based on physical examination and medical history, including diagnosis of severe knee pain and disability due to at least one of the following: to. primary or secondary osteoarthritis b. collagen disorders and/or avascular necrosis of the femoral condyle c. moderate valgus, varus or flexion deformities (hka within ±10°, flexion contracture \<10°) 3. patients consenting and able to complete planned study procedures and follow-up assessments 4. patients informed about the nature of the study who signed the "informed consent" approved by the ethics committee. exclusion criteria: 1. patients aged \< 45 years; 2. patients who have already undergone hip or knee arthroplasty ankle, previous osteotomy, with severe axial deformities or suffering from rheumatoid arthritis, diabetes or neuromuscular diseases. in this way, homogeneity of the investigated cohort will be guaranteed; 3. pregnant women. -
aveir remote care system non-significant risk study

Conditions: Cardiac Pacemaker; Cardiac Rhythm Disorder; Bradycardia

Summary: the goal of the study is to understand the performance of the aveir remote care system in an initial patient cohort which will inform the ability to offer a remote follow-up solution to all patients implanted with aveir lp devices.

to collect acute performance data about the aveir remote care system in participants implanted with a compatible dual or single chamber aveir leadless pacemaker system by participants completing remote transmissions with the system

Eligibility criteria:
inclusion criteria: * subject must provide written informed consent prior to any study-related procedure. * subject is willing and has consented to study clinical procedure. * subject is ≥ 18 years of age or age of legal consent, whichever age is greater * subject has an active, appropriately functioning aveir leadless pacemaker system * subject is willing to use the device exclusion criteria: * subject is unable to read/write at a sufficient level to provide informed consent. * subject is unable to make the decision to participate in a clinical investigation on their own or are unable to fully understand all aspects of the investigation that are relevant to the decision to participate. * subject has presence of medical, social, or psychological conditions that, in the investigator's opinion, could confound the study, limit the subject's ability to participate in the clinical investigation .
postoperative active recovery

Conditions: Pelvic Floor Disorders

Summary: this is a study evaluating a novel active recovery program in the immediate postoperative period following pelvic reconstructive surgery.

this is a randomized controlled trial comparing usual care postoperative restrictions and a novel new active recovery program to look at differences in pelvic floor function, patient quality of life, and mental health in between groups.

Eligibility criteria:
inclusion criteria: 1. between the ages of 18 and 89 2. undergoing minimally invasive apical prolapse reconstructive procedure at ohsu. this includes laparoscopic and robotic-assisted sacrocolpopexy, laparoscopic and vaginal uterosacral ligament suspension, and vaginal sacrospinous ligament fixation. we will include patients undergoing concomitant procedures such as hysterectomy and incontinence procedures. 3. have access to reliable email for communication and questionnaires. exclusion criteria: 1. unable to consent 2. unable to read and complete questionnaires in english 3. unable to sustain 30 minutes of moderate walking/activity at baseline (self-reported) 4. use a mobility assistance device such as a walker/cane at baseline 5. balance or stability problems 6. patients on chronic opioids